Puma Biotechnology Q3 2026 Call: Key Checkpoint for Revenue and Pipeline

What happened

Puma Biotechnology reported Q3 2026 earnings and hosted its earnings call on November 6, 2026, with prepared remarks released via Seeking Alpha. Prior disclosures had set expectations for NERLYNX net revenue in the $195–205 million range for 2026 and for alisertib interim data in H1 2026. The call likely addressed these items and provided updated full-year guidance. Investors should review the transcript for specific financial figures. Based on the latest DeepValue report, the stock had been trading around $6.65 with a WAIT rating, awaiting evidence of revenue stability and pipeline success.

Implication

The Q3 2026 call is a key checkpoint for the investment thesis, as it will clarify whether NERLYNX demand remains stable and whether royalty income has recovered from the 2025 China-related decline. If NERLYNX revenue exceeds $205 million with gross-to-net below 24% and royalties stabilize, the bull case becomes more likely, potentially pushing the stock toward $8–9. Conversely, if royalties remain below $5 million per quarter and alisertib data are weak, the bear case of a declining franchise gains traction, with downside toward $4.50. Given the lack of specific figures in this summary, investors should defer to the transcript for exact metrics. Overall, the stock remains a WAIT at current levels, with better entry points below $5.25 or after confirmation of positive pipeline data.

Thesis delta

The thesis remains unchanged pending specific Q3 2026 data. The core question is whether NERLYNX revenue and royalties have reached the thresholds that would warrant an upgrade from WAIT to a more constructive stance. Without concrete numbers, no shift in the investment thesis is warranted at this time.